Ameriprise
ENGN icon

Ameriprise’s enGene Therapeutics ENGN Stock Holding History

Ameriprise’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.63M Buy
+2,675,876
New +$10.9M ﹤0.01% 2600
2024
Q3 		– Sell
-12,524
Closed -$118K – 3956
2024
Q2 		$118K Buy
+12,524
New +$161K ﹤0.01% 3759

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ameriprise's ENGN Position: Q2 2026 in Review

Ameriprise opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 2,675,876 shares worth $4.63M. The stake represents ﹤0.01% of the portfolio and ranks #2600 among its holdings. This is a return to the name: Ameriprise previously reported a position in ENGN as recently as Q2 2024.

Ameriprise first reported a position in ENGN in Q2 2024 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Ameriprise held 2,675,876 shares of enGene Therapeutics worth $4.63M as of Q2 2026.
  • enGene Therapeutics was a new Ameriprise position in Q2 2026.
  • enGene Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2600 holding.
  • Ameriprise first reported a position in enGene Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.